未登录

J

Justin L. Hay

Princess Maxima Center

H指数:21

被引数:1,191

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pharmacokinetics and Safety of Single-Dose Apraglutide in Individuals with Normal and Impaired Hepatic Function: A Phase 1, Open-Label Trial

单次剂量阿帕鲁肽在正常和受损肝功能个体中的药代动力学和安全性：一项1期、开放标签试验

Clinical Pharmacology in Drug Development

IF1.8

2026-01-160

OAAI

Paediatric development of radiopharmaceutical imaging agents and radioligand therapeutics

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2025-12-010

PRE

Pediatric oncology drug development and dosage optimization

FRONTIERS IN ONCOLOGY

IF3.3

2024-01-292

OAAI

Results of a phase 1 dose escalation clinical trial of NXP800, a novel GCN2 activator, in patients with advanced or metastatic solid tumors

MOLECULAR CANCER THERAPEUTICS

IF5.5

2023-12-010

PRE

A review of clinical pharmacology deficiencies of European centralised drug marketing authorisation applications

欧洲集中药品上市许可申请的临床药理学缺陷综述

REGULATORY TOXICOLOGY AND PHARMACOLOGY

IF3.5

2020-12-012

PREAI

Streamlined approval of biosimilars: moving on from the confirmatory efficacy trial

DRUG DISCOVERY TODAY

IF7.5

2020-11-0134

OAAI

Lack of Detection of the Analgesic Properties of PF-05089771, a Selective Nav1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2019-11-1234

OAAI

Analgesic potential of PF-06372865, an α2/α3/α5 subtype-selective GABAA partial agonist, in humans

BRITISH JOURNAL OF ANAESTHESIA

IF9.2

2019-08-0117

OAAI

Reproducibility of a battery of human evoked pain models to detect pharmacological effects of analgesic drugs

EUROPEAN JOURNAL OF PAIN

IF3.4

2019-04-059

OAAI

Effect profile of paracetamol, 9-THC and promethazine using an evoked pain test battery in healthy subjects

EUROPEAN JOURNAL OF PAIN

IF3.4

2018-04-2516

PREAI

Demonstration of an anti-hyperalgesic effect of a novel pan-Trk inhibitor PF-06273340 in a battery of human evoked pain models

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2017-11-2816

OAAI

Respiratory Effects of the Nociceptin/Orphanin FQ Peptide and Opioid Receptor Agonist, Cebranopadol, in Healthy Human Volunteers

IF9.1

2017-04-0150

PREAI

The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2017-01-0925

OAAI

Pharmacokinetics and pharmacodynamics of intrathecally administered Xen2174, a synthetic conopeptide with norepinephrine reuptake inhibitor and analgesic properties

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2016-12-1615

OAAI

Quantifying Beta-Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling

CTS-Clinical and Translational Science

IF2.8

2016-10-154

OAAI

No evidence of potentiation of buprenorphine by milnacipran in healthy subjects using a nociceptive test battery

EUROPEAN JOURNAL OF PAIN

IF3.4

2016-09-215

PREAI

Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2016-07-1420

OAAI

A literature review on the pharmacological sensitivity of human evoked hyperalgesia pain models

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2016-07-0831

OAAI

Pharmacokinetics and pharmacodynamics of multiple doses of BG00010, a neurotrophic factor with anti-hyperalgesic effects, in patients with sciatica

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2016-05-1319

OAAI

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

使用集成的多模式疼痛任务电池确定疼痛检测和耐受阈值

JOVE-JOURNAL OF VISUALIZED EXPERIMENTS

IF1

2016-04-1410

OAAI